



KEY FEATURES



High Growth Potential

CHB enables investors to access high growth potential through companies central to the development of biotechnology in China.



Targeted Exposure

CHB delivers targeted exposure to an emerging theme and industry.



ETF Efficiency

In a single trade, CHB delivers access to dozens of companies with high exposure to the biotech theme in China.

FUND DETAILS

Inception Date	09/22/2020
Underlying Index	Solactive China Biotech Innovation Index
Number of Holdings	27
Assets Under Management	\$1.53 mil
Total Expense Ratio	0.65%
Distribution Frequency	Semi-Annually

TRADING DETAILS

Ticker	CHB
CUSIP	37954Y251
Exchange	NASDAQ
Bloomberg IOPV Ticker	CHBIV
Index Ticker	SOLCHB

PERFORMANCE (%)

	Current Quarter	Year to Date	One Year	Three Year	Cumulative Since Inception
CHB at NAV	-	-	-	-	1.52%
CHB at Market Price	-	-	-	-	2.39%
Solactive China Biotech Innovation Index	-	-	-	-	1.54%


TOP 10 HOLDINGS (%)

Holdings Subject to Change

BeiGene Ltd	10.59%	Hualan Biological Engineering Inc	5.32%
Wuxi Biologics Cayman Inc	9.37%	BGI Genomics Co Ltd	4.71%
Shenzhen Kangtai Bio Prod Co Ltd	8.58%	Walvax Biotechnology Co Ltd	4.65%
Changchun High & New Tech Inc	7.82%	Zai Lab Ltd	4.29%
Sino Biopharmaceutical Ltd	6.81%	Zhejiang Wolwo Bio-Pharma Co Ltd	4.00%

The performance data quoted represents past performance and does not guarantee future results. Investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost. Current performance may be higher or lower than the performance quoted. Returns for periods greater than one year are annualized. Market price returns are based upon the midpoint of the bid/ask spread at the close of the exchange and do not represent the returns you would receive if you traded shares at other times. For performance data current to the most recent month end, please call 1-888-493-8631, or visit www.globalxetfs.com.

INDUSTRY BREAKDOWN (%)



● Biotechnology	60.77%
● Pharmaceuticals	24.69%
● Life Sciences Tools & Services	13.12%
● Health Care Distributors	0.98%
● Agricultural Products	0.44%



DEFINITIONS

Solactive China Biotech Innovation Index

The Solactive China Biotechnology Innovation Index is designed to provide exposure to exchange-listed companies that are directly involved in China's biotechnology industry. In constructing the index, the Solactive utilizes FactSet Industry classifications to identify companies that are directly involved in the biotechnology industry. Only those securities classified in the biotechnology industry according to FactSet as of each rebalance date are eligible for inclusion in the index. The index is weighted according to a modified capitalization weighting methodology and is reconstituted and re-weighted semi-annually.

Global X Management Company, LLC serves as an advisor to the Global X Funds. The Funds are distributed by SEI Investments Distribution Co. (SIDCO, 1 Freedom Valley Drive, Oaks, PA, 19456), which is not affiliated with Global X Management Company, LLC or Mirae Asset Global Investments.

Investing involves risk, including the possible loss of principal. International investments may involve risk of capital loss from unfavorable fluctuation in currency values, from differences in generally accepted accounting principles, or from economic or political instability in other nations. Emerging markets involve heightened risks related to the same factors as well as increased volatility and lower trading volume. Investments in securities in the Biotechnology and Health Care sectors can be affected by government regulations, rapid product obsolescence, intense industry competition and loss or impairment of patents or intellectual property rights. Technology companies and companies that rely heavily on technology tend to be more volatile than the overall market, and are also heavily dependent on patent and intellectual property rights. Securities focusing on a single country and narrowly focused investments may be subject to higher volatility. CHB is non-diversified.

Shares of ETFs are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions will reduce returns. Global X NAVs are calculated using prices as of 4:00 PM Eastern Time. Indices are unmanaged and do not include the effect of fees, expenses or sales charges. One cannot invest directly in an index.

Global X Funds are not sponsored, endorsed, issued, sold or promoted by Solactive AG, nor does Solactive AG make any representations regarding the advisability of investing in the Global X Funds. Neither SIDCO, Global X nor Mirae Asset Global Investments are affiliated with Solactive AG.

Since the Fund's shares typically do not trade in the secondary market until several days after the Fund's inception, for the period from inception to the first day of secondary market trading in Shares, the NAV of the Fund is used to calculate market returns.

Carefully consider the fund's investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in the fund's full or summary prospectus, which may be obtained by calling 1.888.493.8631, or by visiting globalxetfs.com. Please read the prospectus carefully before investing.